These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21191855)

  • 1. Estimating area under the curve and relative exposure in a pharmacokinetic study with data below quantification limit.
    Fang L; Chen P; Ke C; Lee E
    J Biopharm Stat; 2011 Jan; 21(1):66-76. PubMed ID: 21191855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved designs for dose escalation studies using pharmacokinetic measurements.
    Piantadosi S; Liu G
    Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian approach for PK/PD modeling with PD data below limit of quantification.
    Zhou H; Hartford A; Tsai K
    J Biopharm Stat; 2012; 22(6):1220-43. PubMed ID: 23075019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies.
    Cheung BW; Cartier LL; Russlie HQ; Sawchuk RJ
    Fundam Clin Pharmacol; 2005 Jun; 19(3):347-54. PubMed ID: 15910659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the concentration curves directly in a pharmacokinetics, bioavailability/bioequivalence study.
    Liao JJ
    Stat Med; 2005 Mar; 24(6):883-91. PubMed ID: 15558699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and Cmax: a computer simulation analysis.
    Mahmood I; Miller R
    Int J Clin Pharmacol Ther; 1999 Sep; 37(9):439-45. PubMed ID: 10507242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Truncated AUC evaluates effectively the bioequivalence of drugs with long half-lives.
    Endrenyi L; Tothfalusi L
    Int J Clin Pharmacol Ther; 1997 Apr; 35(4):142-50. PubMed ID: 9112134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propensity score estimation with missing values using a multiple imputation missingness pattern (MIMP) approach.
    Qu Y; Lipkovich I
    Stat Med; 2009 Apr; 28(9):1402-14. PubMed ID: 19222021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers.
    DeVeaugh-Geiss AM; Chen LH; Kotler ML; Ramsay LR; Durcan MJ
    Clin Ther; 2010 Jun; 32(6):1140-8. PubMed ID: 20637967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian population approaches to the analysis of dose escalation studies.
    Russu A; De Nicolao G; Poggesi I; Neve M; Gomeni R
    Comput Methods Programs Biomed; 2012 Aug; 107(2):189-201. PubMed ID: 21764475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol.
    Murthy BP; Skee DM; Danyluk AP; Brett V; Vorsanger GJ; Moskovitz BL
    Curr Med Res Opin; 2007 Feb; 23(2):275-84. PubMed ID: 17288681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonparametric estimation of ROC curves in the absence of a gold standard.
    Zhou XH; Castelluccio P; Zhou C
    Biometrics; 2005 Jun; 61(2):600-9. PubMed ID: 16011710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of data analysis strategies for intent-to-treat analysis in pre-test-post-test designs with substantial dropout rates.
    Salim A; Mackinnon A; Christensen H; Griffiths K
    Psychiatry Res; 2008 Sep; 160(3):335-45. PubMed ID: 18718673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple testing for bioequivalence with pharmacokinetic data in 2 x 2 crossover designs.
    Chen YI; Huang CS
    Stat Med; 2009 Dec; 28(28):3567-79. PubMed ID: 19760611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proposal for a standardised identification of the mono-exponential terminal phase for orally administered drugs.
    Scheerans C; Derendorf H; Kloft C
    Biopharm Drug Dispos; 2008 Apr; 29(3):145-57. PubMed ID: 18098336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An accurate substitution method for analyzing censored data.
    Ganser GH; Hewett P
    J Occup Environ Hyg; 2010 Apr; 7(4):233-44. PubMed ID: 20169489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic parameters estimation using adaptive Bayesian P-splines models.
    Jullion A; Lambert P; Beck B; Vandenhende F
    Pharm Stat; 2009; 8(2):98-112. PubMed ID: 18481279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two new covariate adjustment methods for non-inferiority assessment of binary clinical trials data.
    Hou Y; Ding V; Li K; Zhou XH
    J Biopharm Stat; 2011 Jan; 21(1):77-93. PubMed ID: 21191856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating treatment efficacy over time: a logistic regression model for binary longitudinal outcomes.
    Choi L; Dominici F; Zeger SL; Ouyang P
    Stat Med; 2005 Sep; 24(18):2789-805. PubMed ID: 16134133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.